Clinical trials: Multiple Sclerosis, Primary Progressive
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
The primary objective is to establish the safety of administration of intranasal Foralumab in non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple ascending dose format in escalating doses…
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis
- Trial name
- NCT05029609
- Testing
- Intranasal Foralumab Solution
- Sponsor
- Tiziana Life Sciences LTD
Primary Progressive Multiple Sclerosis
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
- Trial name
- ORATORIO-Cort (NCT05974839)
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 732 people
- Sponsor
- State University of New York at Buffalo
Multiple Sclerosis
MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV
MAIN STUDY: The purpose of this study is to determine if teriflunomide will be safe and effective to prevent relapses in patients with relapsing types of MS when switching from natalizumab to teriflunomide in patients at risk for…
- Trial name
- NCT01970410
- Testing
- teriflunomide
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Providence Health & Services
Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis
Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD)…
- Conditions
- Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis, Parkinson s Disease, REM Sleep Behavior Disorder (iRBD)
- Trial name
- NCT07509125
- Testing
- UHR PET/CT scan of the brain with ¹⁸F-FDG, UHR PET/CT scan of the brain with ¹⁸F-PE2I, UHR PET/CT scan of the brain with ¹⁸F-SynVesT-1
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Primary Progressive Multiple Sclerosis
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
This Phase 2 study is intended to serve as a proof of concept for potential treatment with laquinimod in patients with PPMS. The study is also aimed at evaluating 2 doses of laquinimod in this population.
- Trial name
- ARPEGGIO (NCT02284568)
- Testing
- Laquinimod
- Where
- 99 sites in United States, Canada and 8 more
- Volunteers
- 374 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Primary Progressive
Aerobic Exercises for Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) .It is the most common neurological disorders affecting young adults.Multiple sclerosis is an autoimmune disease that…
- Trial name
- NCT04545372
- Testing
- aerobic exercise
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- South Valley University
Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Motor Neuron Disease Progressive Spinal Muscle Atrophy
Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease
Substantial variability exists in the onset, and rate of degeneration across individuals with Motor Neurone Disease (MND) or Amyotrophic Lateral Sclerosis (ALS).
- Conditions
- Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Motor Neuron Disease Progressive Spinal Muscle Atrophy, Primary Lateral Sclerosis, Multiple Sclerosis
- Trial name
- NCT06320444
- Testing
- 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)
- Where
- Ireland
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Dublin, Trinity College
Multiple Sclerosis
Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina
This observational study is being conducted to evaluate the usefulness of the MSFC and its relationship with EDSS scores in subjects with MS in Argentina.
- Trial name
- NCT01080014
- Where
- Argentina
- Volunteers
- 252 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Primary Progressive Multiple Sclerosis
Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
This study aims to evaluate safety and efficacy of dimethyl fumarate treatment in patients with primary progressive multiple sclerosis (PPMS).
- Trial name
- FUMAPMS (NCT02959658)
- Testing
- Dimethyl fumarate
- Where
- Denmark
- Volunteers
- 54 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multiple Sclerosis, Primary Progressive
Hydroxychloroquine in Primary Progressive Multiple Sclerosis
The purpose of this clinical trial is to determine if HCQ in a dose of 400mg daily can prevent worsening of walking ability in people PPMS. The number of participants in this study will be 35.
- Trial name
- NCT02913157
- Testing
- Hydroxychloroquine
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University of Calgary
Multiple Sclerosis
Supported Treadmill Training for Progressive Multiple Sclerosis
This study is a pilot trial to evaluate the effects of supported treadmill walking in patients with primary progressive multiple sclerosis (MS) on functional and psychosocial outcomes.
- Trial name
- NCT01339234
- Testing
- Body-weight supported treadmill training
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Hicks, Audrey, Ph.D.
Primary Progressive Multiple Sclerosis, Hemiparesis
Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis
Participants will receive intensive therapy through a video game in their own homes for 1 month. The game is operated by movements of the body (no controller needed) and acts like a virtual therapist.
- Trial name
- NCT03094364
- Testing
- Gaming CI Therapy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Massachusetts, Lowell
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis
MUSCLE - Nordic Walking in MUltiple SCLErosis
The aim of the study is to analyze the effects of Nordic Walking and free walking in the clinical-functional, postural balance, motor control, muscular echographic quality, and gait analysis (pendulum gait mechanism), in people…
- Conditions
- Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- MUSCLE (NCT05385731)
- Testing
- Nordic Walking (NWG), Free Walking (FWG), Health Education (HEG)
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Leonardo A. Peyré-Tartaruga
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
Multiple sclerosis (MS) is a chronic inflammatory disorder affecting the central nervous system that is characterized pathologically by focal demyelinating lesions in the brain parenchyma.
- Trial name
- NCT02253264
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
This study is a single-center, open-label, single-arm, exploratory clinical study to evaluate the safety, tolerability, and preliminary efficacy of S103（BCMA-CAR T ）cells in the treatment of progressive or refractory multiple…
- Conditions
- Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis, Multiple Sclerosis (MS) Secondary Progressive, Refractory Multiple Sclerosis
- Trial name
- RESET-MS (NCT07587125)
- Testing
- S103 cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Xijing Hospital
Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis.
- Conditions
- Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
- Trial name
- NCT01466114
- Testing
- estriol, Norethindrone
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles
Multiple Sclerosis
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.
REPAIR-MS is a single-center open label, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed…
- Trial name
- REPAIR-MS (NCT03993171)
- Testing
- gold nanocrystals
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Clene Nanomedicine
Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg administered twice a day orally versus a placebo as a modifying treatment of the disease in patients with the progressive forms of Multiple…
- Trial name
- NCT02273635
- Testing
- Andrographolides
- Where
- Chile
- Volunteers
- 68 people
- Sponsor
- Innobioscience SpA
Neurodegenerative Diseases, Alzheimer Disease
Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study
In this retrospective register study, clinically classified individuals with neurodegenerative disease from the years 2010-2021 will be verified from the clinical records from KUH and Oulu University Hospital (OUH).
- Conditions
- Neurodegenerative Diseases, Alzheimer Disease, Frontotemporal Dementia, Lewy Body Disease
- Trial name
- DEGERWD (NCT06209515)
- Where
- Finland
- Volunteers
- 61,292 people
- Sponsor
- Kuopio University Hospital